Molecular dynamics simulations reveal key roles of the LIF receptor in the assembly of human LIF signaling complex
- PMID: 39989618
- PMCID: PMC11847480
- DOI: 10.1016/j.csbj.2025.01.014
Molecular dynamics simulations reveal key roles of the LIF receptor in the assembly of human LIF signaling complex
Abstract
Leukemia inhibitory factor (LIF) is a critical cytokine involved in various biological processes, including stem cell self-renewal, inflammation, and cancer progression. Structural studies have revealed how LIF forms a functional signaling complex. However, the dynamic binding pattern of the complex remains inadequately clarified. In this study, we employed molecular dynamics (MD) simulations to investigate the recognition and binding mechanisms of LIF, revealing a preferential affinity for LIF Receptor (LIFR) over gp130, attributable to a larger buried surface area at the LIF-LIFR interface. Key residues F178 and K181 in FXXK motif, along with K124 in LIF helix B, mediate hydrophobic interactions, hydrogen bonding and allosteric regulation, collectively stabilizing the LIF-LIFR interaction. We propose that the unique N-terminal extension of LIF enables signaling without requiring the additional receptor subunit beyond gp130 and LIFR, as verified by cell proliferation assays, distinguishing it from other cytokines in the LIF family. Additionally, analysis of domain fluctuations revealed that the LIF-LIFR interface undergoes less angular displacement compared to the LIF-gp130 interface, indicating a more stable interaction with LIFR. Together, these findings provide valuable insights into the molecular basis of LIF recognition and binding, offering a dynamic foundation for cytokine engineering.
Keywords: Gp130; LIF; LIFR; Molecular Dynamics.
© 2025 The Authors.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures







Similar articles
-
Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor.J Biol Chem. 2003 Jul 18;278(29):27169-79. doi: 10.1074/jbc.M303168200. Epub 2003 Apr 21. J Biol Chem. 2003. PMID: 12707269
-
Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signaling.J Biol Chem. 2004 Jan 16;279(3):2125-34. doi: 10.1074/jbc.M310103200. Epub 2003 Oct 29. J Biol Chem. 2004. PMID: 14585833
-
LIF receptor-gp130 interaction investigated by homology modeling: implications for LIF binding.Protein Sci. 1998 Apr;7(4):886-96. doi: 10.1002/pro.5560070406. Protein Sci. 1998. PMID: 9568895 Free PMC article.
-
The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights.Biochim Biophys Acta Rev Cancer. 2022 Jul;1877(4):188737. doi: 10.1016/j.bbcan.2022.188737. Epub 2022 Jun 6. Biochim Biophys Acta Rev Cancer. 2022. PMID: 35680099 Free PMC article. Review.
-
Roles of leukemia inhibitory factor receptor in cancer.Int J Cancer. 2025 Jan 15;156(2):262-273. doi: 10.1002/ijc.35157. Epub 2024 Sep 15. Int J Cancer. 2025. PMID: 39279155 Review.
Cited by
-
Biological Actions of Bile Acids via Cell Surface Receptors.Int J Mol Sci. 2025 May 22;26(11):5004. doi: 10.3390/ijms26115004. Int J Mol Sci. 2025. PMID: 40507815 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous